Simeprevir
49 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Rescooped by Andy Fletcher from Hepatitis C New Drugs Review
Scoop.it!

AbbVie Completes Largest Phase III Program of an All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C Genotype 1 - Jan 31, 2014

AbbVie Completes Largest Phase III Program of an All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C Genotype 1 - Jan 31, 2014 | Simeprevir | Scoop.it
ABBVIE COMPLETES LARGEST PHASE III PROGRAM OF AN ALL-ORAL, INTERFERON-FREE THERAPY FOR THE TREATMENT OF HEPATITIS C GENOTYPE 1- NINETY-NINE PERCENT SVR(12) RATES WITH AND WITHOUT RIBAVIRIN IN CERTAIN PATIENT TYPES- EVEN IN DIFFICULT-TO-TREAT PATIENTS (CIRRHOTIC PATIENTS) ACHIEVED 92-96 PERCENT SVR(12) RATES- ABBVIE EXPECTS U.S. LAUNCH IN 2014
Via Krishan Maggon
more...
No comment yet.
Rescooped by Andy Fletcher from Hepatitis C New Drugs Review
Scoop.it!

FDA approves Sovaldi (sofosbuvir, Gilead) for chronic hepatitis C

“ The U.S. Food and Drug Administration today approved Sovaldi (sofosbuvir) to treat chronic hepatitis C virus (HCV) infection.”
Via Krishan Maggon
more...
No comment yet.
Scooped by Andy Fletcher
Scoop.it!

Gilead HCV Drug May Face Price War; Rival AbbVie Up - Investor's Business Daily

Gilead HCV Drug May Face Price War; Rival AbbVie Up - Investor's Business Daily | Simeprevir | Scoop.it
“Gilead HCV Drug May Face Price War; Rival AbbVie Up Investor's Business Daily Gilead Sciences' (GILD) newly approved hepatitis C drug Sovaldi came under fire for its price from pharmacy benefit manager Express Scripts (ESRX) Tuesday, as rival...”
more...
No comment yet.
Rescooped by Andy Fletcher from Hepatitis C New Drugs Review
Scoop.it!

Soaring Hepatitis C Drug Prices Make Cures Costly ~ HCV Research and News

RT @hcvresearchnews: Soaring Hepatitis C Drug Prices Make Cures Costly - http://t.co/6Tqe3h7WDR #HepC #HCV

Via Krishan Maggon
more...
No comment yet.
Rescooped by Andy Fletcher from E-HEALTH - E-SANTE - PHARMAGEEK
Scoop.it!

Less than a third of #pharma websites are optimised for mobile #hcsmeufr

Less than a third of #pharma websites are optimised for mobile #hcsmeufr | Simeprevir | Scoop.it
Other insights from the Manhattan Research ePharma Competitive Analysis series: Pharmas continue to shy away from social media - according to the research only 17 percent of unbranded websites reviewed had a dedicated social media presence. Instead, many brands opt for peer-to-peer elements that aren't live or tied to social media platforms, such as inviting visitors to submit their stories or mentor and advocate programs.One-third of unbranded websites reviewed linked to product websites.Nearly half of all websites tracked offered branded patient support programs, often promoted under different names on product and unbranded sites.Emerging models of pharma website design, such as multi-indication hubs like Genentech's BioOncology.com, portal-like sites such as Sanofi's The DX, and branded support programs like Novartis' Care to Care Program for Exelon Patch, are breaking the mold. Despite pharma's overall struggle with mobile and social, the reports highlight instances where some brands are trailblazing. "There are pockets of strong digital innovation today, particularly among pharma brands with new products," said Manhattan Research's Monique Levy. "Multiple sclerosis, hepatitis C, and oncology are three categories worth watching closely."
Via Andrew Spong, Lionel Reichardt / le Pharmageek
more...
No comment yet.
Scooped by Andy Fletcher
Scoop.it!

New group of oral hepatitis C drugs near US approval - Reuters UK

New group of oral hepatitis C drugs near US approval - Reuters UK | Simeprevir | Scoop.it
“San Francisco Chronicle New group of oral hepatitis C drugs near US approval Reuters UK (Reuters) - Patients infected with the liver-destroying hepatitis C virus should soon have better treatment options as new tablets from Gilead Sciences and...”
more...
No comment yet.
Scooped by Andy Fletcher
Scoop.it!

Medivir: Janssen Has Acquired an NS5a Replication Complex Inhibitor That Will Be Evaluated with Simeprevir in Future Clinical Development

Medivir: Janssen Has Acquired an NS5a Replication Complex Inhibitor That Will Be Evaluated with Simeprevir in Future Clinical Development | Simeprevir | Scoop.it
“From BioPortfolio: Regulatory News: Medivir AB (OMX: MVIR) announced that Janssen Pharmaceuticals, Inc. (Janssen) has acquired the investigational compound GSK2336805 (GSK805), an...”
more...
No comment yet.
Scooped by Andy Fletcher
Scoop.it!

Janssen to present simeprevir data at AASLD meeting

Janssen to present simeprevir data at AASLD meeting | Simeprevir | Scoop.it
“Zenopa (Pharmaceutical News: Janssen to present simeprevir data at AASLD meeting http://t.co/Ve2ZGXjlqm)”
more...
No comment yet.
Scooped by Andy Fletcher
Scoop.it!

J&J snaps up an NS5A inhibitor from GlaxoSmithKline for hep C cocktail - FierceBiotech

J&J snaps up an NS5A inhibitor from GlaxoSmithKline for hep C cocktail - FierceBiotech | Simeprevir | Scoop.it
“Medical Marketing and Media J&J snaps up an NS5A inhibitor from GlaxoSmithKline for hep C cocktail FierceBiotech J&J says it will waste no time in pushing ahead with new mid-stage studies of GSK2336805 in combination with simeprevir (TMC435) and...”
more...
No comment yet.
Scooped by Andy Fletcher
Scoop.it!

Hepatitis C Research and News: Simeprevir data from COSMOS study in Hepatitis C patients will be presented as late-breaking presentation at AASLD

“Simeprevir data from COSMOS study in #HepC patients will be presented as late-breaking presentati ... http://t.co/FD8wwIyVVX #Liver2013 #HCV”
more...
No comment yet.
Rescooped by Andy Fletcher from Pharma & Medical Devices
Scoop.it!

Vertex sales lag as hep C patients pass on Incivek - FiercePharma

Vertex sales lag as hep C patients pass on Incivek - FiercePharma | Simeprevir | Scoop.it
Vertex Pharmaceuticals ($VRTX) watched its once-high-flying hepatitis C drug go into a nosedive for the fourth quarter. Incivek sales plummeted by 51% to $222.8 million, as fewer new patients elected to start therapy. There's good reason for that: A host of new, oral treatments are racing toward the market, so some patients are waiting around. Though Incivek was seen as a ground-breaking drug when it was approved in 2011, its hep C rivals have made a lot of progress since then. Now, the promise of an all-oral cocktail--rather than Incivek added to injectable interferon--is just too alluring.
Via Richard Meyer
more...
No comment yet.
Rescooped by Andy Fletcher from Hepatitis C New Drugs Review
Scoop.it!

Gilead's Sofosbuvir Gets New Name, Price, Headaches

“ New York Daily News Gilead's Sofosbuvir Gets New Name, Price, Headaches Motley Fool Sovaldi's stiff price tag is also a big jump from the $50,000-a-year price commanded by Johnson & Johnson's (NYSE: JNJ ) and Vertex's Incivek, and Merck's Victrelis.”
Via Krishan Maggon
more...
No comment yet.
Rescooped by Andy Fletcher from Hepatitis C New Drugs Review
Scoop.it!

Gilead Hep C Drug Launch Threatened by Price Concerns

Gilead Hep C Drug Launch Threatened by Price Concerns TheStreet.com The top medical officer for pharmacy benefits manager Express Scripts expressed concerns about high pricing for the new crop of hepatitis C pills, most notably Gilead Sciences $1000 a pill newly approved drug
Via Krishan Maggon
more...
No comment yet.
Rescooped by Andy Fletcher from ORGANIC CHEMISTRY INTERNATIONAL
Scoop.it!

FDA Approves Olysio (simeprevir) for Hepatitis C Virus

FDA Approves Olysio (simeprevir) for Hepatitis C Virus | Simeprevir | Scoop.it
“ simeprevir CAS number 923604-59-5 Formula C38H47N5O7S2 Weight 749.93908 November 22, 2013 -- The U.S. Food and Drug Administration today approved Olysio (simeprevir), a new therapy to treat chronic...”
Via Anthony M Crasto DR.
more...
No comment yet.
Scooped by Andy Fletcher
Scoop.it!

Docs won't rush to new Gilead HCV pill: poll - Medical Marketing and Media

Docs won't rush to new Gilead HCV pill: poll - Medical Marketing and Media | Simeprevir | Scoop.it
“Docs won't rush to new Gilead HCV pill: poll Medical Marketing and Media On the eve of the FDA's pending decision on Gilead's sofosbuvir, a MedLIVE PULSE survey—conducted by WorldOne Interactive for MM&M of 48 US hepatologists—suggests doctors may...”
more...
No comment yet.
Scooped by Andy Fletcher
Scoop.it!

Simeprevir with interferon effective for HIV/HCV co-infected people with ... - aidsmap

Simeprevir with interferon effective for HIV/HCV co-infected people with ... - aidsmap | Simeprevir | Scoop.it
“Simeprevir with interferon effective for HIV/HCV co-infected people with ...”
more...
No comment yet.
Scooped by Andy Fletcher
Scoop.it!

J&J snaps up GSK antiviral for hep C combo - PharmaTimes

J&J snaps up GSK antiviral for hep C combo - PharmaTimes | Simeprevir | Scoop.it
“Medical Marketing and Media J&J snaps up GSK antiviral for hep C combo PharmaTimes It was revealed that Janssen intends to initiate Phase II studies to assess the drug's potential in interferon-free combinations with the investigational protease...”
more...
No comment yet.
Scooped by Andy Fletcher
Scoop.it!

Simeprevir pushes HCV cure rate above 75% for HIV/HCV co-infection - aidsmap

Simeprevir pushes HCV cure rate above 75% for HIV/HCV co-infection - aidsmap | Simeprevir | Scoop.it
“ aidsmap Simeprevir pushes HCV cure rate above 75% for HIV/HCV co-infection aidsmap These next-generation HCV protease inhibitors "represent a significant advance" over boceprevir (Victrelis) and telaprevir (Incivo or Incivek), Dieterich said, as...”
more...
No comment yet.
Scooped by Andy Fletcher
Scoop.it!

Medivir: Janssen Has Acquired an NS5a Replication Complex Inhibitor That Will ... - PharmiWeb.com (press release)

Medivir: Janssen Has Acquired an NS5a Replication Complex Inhibitor That Will ... - PharmiWeb.com (press release) | Simeprevir | Scoop.it
“Medivir: Janssen Has Acquired an NS5a Replication Complex Inhibitor That Will ...”
more...
No comment yet.